Status:
COMPLETED
Seroquel XR in Schizophrenia Relapse Prevention
Lead Sponsor:
AstraZeneca
Conditions:
Schizophrenia Relapse Prevention
Eligibility:
All Genders
18-70 years
Brief Summary
The purpose of the study is to determine whether the Seroquel XR treatment for 6 months improve the relapse prevention in schizophrenic outpatients
Eligibility Criteria
Inclusion
- Schizophrenic outpatients on at least 600 mg Seroquel XR treatment for at least 1 month
Exclusion
- Severe cerebro- and cardiovascular disease, severe hepatic impairment, gravidity
Key Trial Info
Start Date :
October 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2010
Estimated Enrollment :
1600 Patients enrolled
Trial Details
Trial ID
NCT00990626
Start Date
October 1 2009
End Date
July 1 2010
Last Update
November 17 2010
Active Locations (48)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Baja, Hungary
2
Research Site
Barcs, Hungary
3
Research Site
Budapest, Hungary
4
Research Site
Cegléd, Hungary